Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, Nitin Jain, Naval Daver, Sherry Pierce, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Guillermo Garcia-Manero, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (15): 1373–1377.

https://doi.org/10.1182/blood.2021011817

Published: 2021

Journal Articles

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Blood (2017) 129 (18): 2584–2587.

https://doi.org/10.1182/blood-2016-11-749903

Published: 2017

Includes: Supplemental data

Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Blood (2017) 129 (10): 1275–1283.

https://doi.org/10.1182/blood-2016-09-736686

Published: 2017

Journal Articles

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Preetesh Jain, MBBS,MDDM,PhD, Michael J. Keating, MD, Charles Cleeland, Sarah Renner, Huang Xuelin, Graciela Nogueras Gonzalez, David M. Harris, William Wierda, MD PhD, Courtney DiNardo, MD, Naveen Pemmaraju, Nitin Jain, MD, Philip Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, Zeev Estrov, MD

Blood (2015) 126 (23): 2943.

https://doi.org/10.1182/blood.V126.23.2943.2943

Published: 2015

Journal Articles

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Gail J Roboz, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Courtney DiNardo, MD, Darla Miller, Zeev Estrov, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Srdan Verstovsek, MD PhD, Hagop M. Kantarjian, MD, Elias Jabbour

Blood (2015) 126 (23): 94.

https://doi.org/10.1182/blood.V126.23.94.94

Published: 2015

Journal Articles

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

Naval Daver, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Lingsha Zhou, Sherry Pierce, BSN, BA, Naveen Pemmaraju, MD, Elias Jabbour, Courtney DiNardo, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Marina Konopleva, MD PhD, Franklin Wynn, Stephanie Van Derbur, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD

Blood (2015) 126 (23): 823.

https://doi.org/10.1182/blood.V126.23.823.823

Published: 2015

Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 910.

https://doi.org/10.1182/blood.V126.23.910.910

Published: 2015

Journal Articles

Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)

Blood (2015) 126 (23): 2877.

https://doi.org/10.1182/blood.V126.23.2877.2877

Published: 2015

Journal Articles

Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS

Koichi Takahashi, MD, Feng Wang, PhD, Seth Sahil, Jianhua Zhang, Curtis Gumbs, Ghayas C. Issa, MD, Christopher B. Benton, MD, Sherry Pierce, BSN, BA, Elias Jabbour, Naval Daver, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Hagop M. Kantarjian, MD, Andrew Futreal, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 1663.

https://doi.org/10.1182/blood.V126.23.1663.1663

Published: 2015

Journal Articles

TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD, Carlos E Bueso-Ramos, Tapan Kadia, MD, Elias Jabbour, Courtney DiNardo, MD, Naval Daver, MD, Sherry Pierce, BSN, BA, Andrew Futreal, PhD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 1681.

https://doi.org/10.1182/blood.V126.23.1681.1681

Published: 2015

Journal Articles

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia

Tapan Kadia, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Koichi Takahashi, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Kapil N. Bhalla, MD, Marina Konopleva, MD PhD, Naval Daver, MD, Courtney DiNardo, MD, Prithviraj Bose, MD, Keyur P. Patel, MD PhD, Sherry Pierce, BSN, BA, Hagop M. Kantarjian, MD

Blood (2015) 126 (23): 564.

https://doi.org/10.1182/blood.V126.23.564.564

Published: 2015

Journal Articles

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

Maliha Khan, MD, Bodden Kristy, Tapan Kadia, MD, Alessandra Ferrajoli, MD, Yesid Alvarado, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Courtney DiNardo, MD

Blood (2015) 126 (23): 1691.

https://doi.org/10.1182/blood.V126.23.1691.1691

Published: 2015

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, C. Cameron Yin, MDPhD, Koji Sasaki, MD, Guillermo Garcia-Manero, MD, Courtney DiNardo, MD, Koichi Takahashi, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval Daver, MD, Tapan Kadia, MD, Srdan Verstovsek, MD, Sherry Pierce, BSN, BA, Elias Jabbour

Blood (2015) 126 (23): 4874.

https://doi.org/10.1182/blood.V126.23.4874.4874

Published: 2015

Journal Articles

The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jeffrey L. Jorgensen, MD PhD, Sa Wang, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Koji Sasaki, MD, Courtney DiNardo, MD, Tapan Kadia, MD, Jane Autry, RN, Rebecca Garris, Elias Jabbour

Blood (2015) 126 (23): 3771.

https://doi.org/10.1182/blood.V126.23.3771.3771

Published: 2015

Journal Articles

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Blood (2015) 126 (23): 3776.

https://doi.org/10.1182/blood.V126.23.3776.3776

Published: 2015

Journal Articles

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Tapan Kadia, MD, Farhad Ravandi, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Elias Jabbour, Steven M. Kornblau, MD, Srdan Verstovsek, MD, William Wierda, MD PhD, Jan A Burger, MD PhD, Zeev Estrov, MD, Courtney DiNardo, MD, Xiao Qin Dong, Naveen Pemmaraju, MD, Maro Ohanian, DO, Koichi Takahashi, MD, Stephany Hendrickson, RN, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 4779.

https://doi.org/10.1182/blood.V126.23.4779.4779

Published: 2015

Journal Articles

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Guillermo Garcia-Manero, MD, Hui Yang, MD PhD, Zhihong Fang, Courtney DiNardo, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Ricardo Delumpa, RN, Christopher Loiselle, RN, Susan Denton, RN, Whitney Smith, Hiroyuki Iwamura, PhD, Teletha Gipson, PhD, Michele Rosner, MS, Timothy Madden, PharmD, Thomas J. Myers, MD, Linda J. Paradiso, DVM, MBA

Blood (2015) 126 (23): 3800.

https://doi.org/10.1182/blood.V126.23.3800.3800

Published: 2015

Journal Articles

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Hagop Kantarjian, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Naval Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, William Plunkett, PhD

Blood (2015) 126 (23): 3804.

https://doi.org/10.1182/blood.V126.23.3804.3804

Published: 2015

NARROW

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Ruxolitinib Reduces Cytokine/Chemokine Levels and Improves Fatigue and Chronic Lymphocytic Leukemia (CLL)-Related Symptoms in CLL Patients Not Requiring Systemic Therapy

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)

Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS

TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia

Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD

The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only